(AOF) – Medesis Pharma announces today that it has obtained financing and entered into an agreement with its clinical research organization (CRO) for the analysis of the results of the 1st phase of the clinical trial of its candidate for the treatment of the disease of Alzheimer’s. This biotech developing drug candidates based on its proprietary technology for administering active ingredients in nanomicelles orally, Aonys, specifies that the results are now expected at the end of September and the cash flow horizon is extended until the beginning of October 2024.
The CRO should pay 150,000 euros to Medesis Pharma, including 120,000 euros now. The company has also obtained financing of 450,000 euros from active historical shareholders, and expects 538,000 euros in tax credits for July.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.